S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Janjigian
    Janjigian
  8. Jhanwar
    Jhanwar
  9. Tang
    Tang
  10. Clarkson
    Clarkson

Groups

  1. Department of Medicine (280)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Thoracic Oncology (45)
  10. Department of Pathology and Laboratory Medicine (43)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (255)
  3. Book Section (20)
  4. Review (16)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (280)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (5)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (635)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The p110alpha/PI3K controls endothelial cell rearrangements during angiogenesis by stimulating MLC2 dephosphorylation
    Meeting Abstract

    Graupera, M.; Angulo-Urarte, A.; Kobialka, P.; Castel, P.; Casado, P. M.; Affolter, M.; Gerhardt, H.; Belting, H. G.; Cutillas, P. R.
    Journal of Vascular Research (2017)

    Fulltext@MSK | Save
  • Systematic review of the role of targeted therapy in metastatic neuroendocrine tumors
    Journal Article

    Lee, A.; Chan, D. L.; Wong, M. H.; Li, B. T.; Lumba, S.; Clarke, S. J.; Samra, J.; Pavlakis, N.
    Neuroendocrinology (2017)

    Fulltext@MSK | Save
  • Primary ovarian insufficiency in childhood cancer survivors: A report from the St Jude Lifetime Cohort (SJLIFE)
    Meeting Abstract

    Chemaitilly, W.; Li, Z.; Krasin, M.; Wilson, C.; Green, D.; Klosky, J.; Barnes, N.; Clark, K.; Frenandez-Pineda, I.; Metzger, M.; more...
    Hormone Research in Paediatrics (2016)

    Fulltext@MSK | Save
  • Nivolumab monotherapy in metastatic urothelial cancer (mUC): Efficacy (by PD-L1 expression) and safety results from the CheckMate 032 study
    Meeting Abstract

    Jaeger, D.; Sharma, P.; Bono, P.; Kim, J.; Spiliopoulou, P.; Calvo, E.; Pillai, R. N.; Ott, P. A.; de Braud, F.; Morse, M.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Recognizing symptom burden in advanced prostate cancer: A global patient and caregiver survey
    Meeting Abstract

    Schostak, M.; Oh, W. K.; Tombal, B.; Delacruz, A.; Tomlinson, I.; Ripley, A. V.; Drudge-Coates, L.; Mastris, K.; O'Sullivan, J. M.; Shore, N. D.
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • A novel hereditary pancreatic neuroendocrine tumor syndrome associated with biallelic inactivation of the glucagon receptor
    Meeting Abstract

    Tang, L.; Yu, R.
    Neuroendocrinology (2016)

    Fulltext@MSK | Save
  • Design of a phase 3, international, prospective, randomized, double-blind, placebo (PBO) controlled study assessing efficacy and safety of lanreotide autogel/depot (LAN) 120 mg in patients with well-differentiated, advanced typical and atypical lung NETs
    Meeting Abstract

    Reidy-Lagunes, D.; Kulke, M.; Wolin, E.; Mirakhur, B.; Massien, C.; Caplin, M.; Baudin, E.
    Neuroendocrinology (2016)

    Fulltext@MSK | Save
  • CheckMate 017 and 057 studies of nivolumab vs docetaxel in patients with advanced NSCLC: 2-year-update and exploratory cytokine profile analyses
    Meeting Abstract

    Eberhardt, W. E. E.; Borghaei, H.; Brahmer, J. R.; Horn, L.; Ready, N.; Steins, M.; Felip, E.; Paz-Ares, L. G.; Arrieta, O.; Barlesi, F.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Synergistic inhibition of chromatin modifiers reverses a leukemogenic gene expression program in NPM1 mutant leukemia
    Meeting Abstract

    Kühn, M. W. M.; Song, E.; Feng, Z.; Sinha, A.; Chen, C. W.; Deshpande, A. J.; Cusan, M.; Farnoud, N. R.; Koche, R. P.; Bradner, J. E.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study
    Meeting Abstract

    Grünwald, V.; Motzer, R. J.; Sharma, P.; Escudier, B.; McDermott, D. F.; George, S.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Plimack, E. R.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save